drugset / Trial / NCT00770692
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.
Timeline
- Start
- 2008-10
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eszopiclone | Small molecule | 1 mg | Oral |
| Subject | Eszopiclone | Small molecule | 2 mg | Oral |
| Subject | Eszopiclone | Small molecule | 3 mg | Oral |